Analytical Data
-
基因名
FBXO22
- Application
-
别名
0610033L19Rik; 1600016C16Rik; F box only protein 22; F box protein 22; F box protein FBX22p44 ; F-box only protein 22; F-box protein FBX22p44; FBX22; FBX22_HUMAN; FBXO 22; FBXO22; FIST domain containing 1; FISTC1; FLJ13986; MGC124731; MGC31799
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8NEZ5
-
表达区间
1-403aa
-
氨基酸序列
MEPVGCCGEC RGSSVDPRST FVLSNLAEVV ERVLTFLPAK ALLRVACVCR LWRECVRRVL RTHRSVTWIS AGLAEAGHLE GHCLVRVVAE ELENVRILPH TVLYMADSET FISLEECRGH KRARKRTSME TALALEKLFP KQCQVLGIVT PGIVVTPMGS GSNRPQEIEI GESGFALLFP QIEGIKIQPF HFIKDPKNLT LERHQLTEVG LLDNPELRVV LVFGYNCCKV GASNYLQQVV STFSDMNIIL AGGQVDNLSS LTSEKNPLDI DASGVVGLSF SGHRIQSATV LLNEDVSDEK TAEAAMQRLK AANIPEHNTI GFMFACVGRG FQYYRAKGNV EADAFRKFFP SVPLFGFFGN GEIGCDRIVT GNFILRKCNE VKDDDLFHSY TTIMALIHLG SSK
-
分子量
44.5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FBXO22 is a member of the F-box protein family, which plays a crucial role in the ubiquitin-proteasome system, a key pathway for protein degradation in eukaryotic cells. F-box proteins, including FBXO22, serve as substrates for SCF (SKP1-Cullin-F-box) E3 ubiquitin ligase complexes, facilitating the ubiquitination and subsequent proteasomal degradation of specific target proteins. Research into FBXO22 has gained momentum due to its potential involvement in various biological processes, including cell cycle regulation, signal transduction, and cellular stress responses. Dysregulation of FBXO22 and its associated pathways has been implicated in several diseases, particularly cancer, where aberrant protein turnover can lead to uncontrolled cell proliferation. Additionally, studies have suggested that FBXO22 may interact with key oncogenic pathways, positioning it as a potential biomarker or therapeutic target in oncology. Given the complexity and significance of its roles, the recombinant expression and characterization of FBXO22 can provide valuable insights into its molecular functions and interactions, offering prospects for understanding its contributions to cellular homeostasis and disease mechanisms. Hence, investigating FBXO22, through recombinant protein studies, can pave the way for novel therapeutic interventions and enhance our comprehension of its role in health and disease.
